Abstract:Primary immune regulatory disorders (PIRDs) are inborn errors of immunity caused by a loss in the regulatory mechanism of the inflammatory or immune response, leading to impaired immunological tolerance or an exuberant inflammatory response to various stimuli due to loss or gain of function mutations. Whilst PIRDs may feature susceptibility to recurrent, severe, or opportunistic infection in their phenotype, this group of syndromes has broadened the spectrum of disease caused by defects in immunity-related genes to include autoimmunity, autoinflammation, lymphoproliferation, malignancy, and allergy; increasing focus on PIRDs has thus redefined the classical 'primary immunodeficiency' as one aspect of an overarching group of inborn errors of immunity. The growing number of genetic defects associated with PIRDs has expanded our understanding of immune tolerance mechanisms and prompted identification of molecular targets for therapy. However, PIRDs remain difficult to recognize due to incomplete penetrance of their diverse phenotype, which may cross organ systems and present to multiple clinical specialists prior to review by an immunologist. Control of immune dysregulation with immunosuppressive therapies must be balanced against the enhanced infective risk posed by the underlying defect and accumulated end-organ damage, posing a challenge to clinicians. Whilst allogeneic hematopoietic stem cell transplantation may correct the underlying immune defect, identification of appropriate patients and timing of transplant is difficult. The relatively recent description of many PIRDs and rarity of individual genetic entities that comprise this group means data on natural history, clinical progression, and treatment are limited, and so international collaboration will be needed to better delineate phenotypes and the impact of existing and potential therapies. This review explores pathophysiology, clinical features, current therapeutic strategies for PIRDs including cellular platforms, and future directions for research.

New immunodeficiency syndromes that help us understand the IFN-mediated antiviral immune response

Viral infections in humans and mice with genetic deficiencies of the type I IFN response pathway

Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases

In search of a function for human type III interferons: insights from inherited and acquired deficits

IRF and STAT Transcription Factors - From Basic Biology to Roles in Infection, Protective Immunity, and Primary Immunodeficiencies

A Commentary of “type I Interferon Deficiency Can Lead to Severe COVID-19” in 10 Remarkable Discoveries from 2020 in Nature

Pathogenic Role of Type I Interferons in HIV-Induced Immune Impairments in Humanized Mice

Human Type I Interferon Antiviral Effects in Respiratory and Reemerging Viral Infections

Too much of a good thing: a review of primary immune regulatory disorders

Invasive Fungal Infection in Primary Immunodeficiencies Other Than Chronic Granulomatous Disease

The autoimmune rheumatological presentation of Common Variable Immunodeficiency Disorders with an overview of genetic testing

Autoimmunity as a continuum in primary immunodeficiency

New Facets of Antibody Deficiencies

Type I and type III interferons: From basic biology and genetics to clinical development for COVID-19 and beyond

Herpesviruses and the Type III Interferon System

Primary and Acquired Immunodeficiencies Associated With Severe Varicella-Zoster Virus Infections

Novel interferonopathies associated with mutations in RIG-I like receptors

The Scope and Impact of Viral Infections in Common Variable Immunodeficiency (CVID) and CVID-like Disorders: A Literature Review

The Interaction Between Human Enteroviruses and Type I IFN Signaling Pathway

The interaction between human enteroviruses and type I IFN signaling pathway.

Viral Innate Immune Evasion and the Pathogenesis of Emerging RNA Virus Infections